Prescription drug · ANDA
Erythromycin NDC 72241-037
Erythromycin 500 mg/1 · Tablet, Film coated · Oral · Modavar Pharmaceuticals LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 72241-037-05 | 72241003705 | 100 TABLET, FILM COATED in 1 BOTTLE (72241-037-05)Marketed from Jul 31, 2021 | |
| 72241-037-22 | 72241003722 | 30 TABLET, FILM COATED in 1 BOTTLE (72241-037-22)Marketed from Jul 31, 2021 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Erythromycin
- Generic name (nonproprietary)
- erythromycin
- Active ingredients
- Erythromycin — 500 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Modavar Pharmaceuticals LLC
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 213628
- Marketing start
- Listing expires
- Other FDA classes
- Decreased Sebaceous Gland Activity (Physiologic effect)Macrolides (Chemical structure)
- Identifiers
- Product ID 72241-037_eb7928f4-e0c7-4f23-a1a8-934d82f5eca4SPL ID eb7928f4-e0c7-4f23-a1a8-934d82f5eca4SPL set ID bc3d091b-1fc8-4f7a-a3c2-8ede87f5faa0RxCUI 197650, 598006UNII 63937KV33D
- Pharmacologic class
- Macrolide Antimicrobial; Macrolide
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N472241003705followed by a unit qualifier and the quantityPackage 72241-0037-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS & USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets and other antibacterial drugs, erythromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 213628
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Erythromycin | Erythromycin 250 mg/1 | Tablet, Film coatedOral | Cadila Pharmaceuticals Limited | 71209-100 |
| Erythromycin | Erythromycin 500 mg/1 | Tablet, Film coatedOral | Cadila Pharmaceuticals Limited | 71209-101 |
| Erythromycin | Erythromycin 500 mg/1 | Tablet, Film coatedOral | Orange Pharmaceuticals USA LLC | 73082-020 |
| Erythromycin | Erythromycin 250 mg/1 | Tablet, Film coatedOral | Orange Pharmaceuticals USA LLC | 73082-010 |
| Erythromycin | Erythromycin 250 mg/1 | Tablet, Film coatedOral | Modavar Pharmaceuticals LLC | 72241-036 |